RS-25259-197

Drugs of the Future

Volumn 21, Issue 9, 1996, Pages 906-910

  Graul, A ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; GRANISETRON; ONDANSETRON; PALONOSETRON; QUIPAZINE; SEROTONIN 3 RECEPTOR; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG;

ARTICLE; BRAIN CORTEX; CELL CULTURE; CELL LINE; DOG; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; ENANTIOMER; GUINEA PIG; ILEUM; INTRAGASTRIC DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; VOMITING;

EID: 0029823297     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1996.021.09.371064     Document Type: Article

References (7)

1. Dvorak, C.A., Kowalczyk, B.A. (F. Hoffmann-La Roche AG). Process for the preparation of 2-(1-azabicyclo[2.2.2]oct-3-yl)-2,4,5,6-tetrahydro-1H-benz[de]isoquinolin-1-one and intermediate product. WO 9601824.
2. 3 receptor antagonists. J Med Chem 1993, 36(18): 2645.
3. Berger, J., Clark, R.D., Eglen, R.M., Smith, W.L., Weinhardt, K.K. (Syntex [USA], Inc.). New tricyclic cpds. AU 9166963, EP 430190, US 5202333.
4. 3 antagonist (RS-25259-197) at high specific activity. J Label Compound Radiopharm 1996, 38(5) 425.
5. 3 receptors, in vitro. Brit J Pharmacol 1995, 114(4): 851.
6. 3 receptor antagonist, in vivo. Brit J Pharmacol 1995, 114(4): 860.
7. 3 receptors. J Neurochem 1995, 65(1): 104.